Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS012 in advanced solid tumors
NCT05388279Phase 1Terminated
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of JS012 in solid tumor (2 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Incidence of Dose-Limiting Toxicity, Incidence and severity of Adverse Events and 3 more. Started Apr 2022; status: terminated.
02
Drugs
JS012
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05388279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388279.